{"id":26167,"date":"2023-12-14T10:07:41","date_gmt":"2023-12-14T04:37:41","guid":{"rendered":"https:\/\/www.delveinsight.com\/blog\/?p=26167"},"modified":"2023-12-14T10:11:25","modified_gmt":"2023-12-14T04:41:25","slug":"augment-101-trial-hits-primary-endpoint","status":"publish","type":"post","link":"https:\/\/www.delveinsight.com\/blog\/augment-101-trial-hits-primary-endpoint","title":{"rendered":"Breakthrough Success: AUGMENT-101 Trial Hits Primary Endpoint with Consistent CR\/CRh Rates Across Adult and Pediatric KMT2Ar AML and ALL Cohorts"},"content":{"rendered":"\n
Date of Abstract presentation<\/td>12th December 2023<\/td><\/tr>
Indications<\/td>Acute Leukemia<\/td><\/tr>
Abstract Number<\/td>LBA-5<\/td><\/tr>
Abstract type<\/td>Poster<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n

According to the data presented at the ASH 2023 conference, as of the July 2023 data cutoff, the pivotal trial AUGMENT-101 included 94 patients with acute leukemia<\/a><\/strong> within the KMT2Ar cohorts. Among them, 57 individuals received central confirmation of their KMT2Ar status, had adequate follow-up, and were part of the population evaluated for efficacy.\u00a0 Among the patients evaluated for efficacy, a notable 63% demonstrated an overall response, while 44% achieved a composite response (CRc).<\/strong> Minimal residual disease (MRD) status was examined in 22 out of the 25 patients who attained a CRc, revealing that 68% were MRD negative. Favorable responses were observed across all major subgroups, including those with varying numbers of prior treatments and prior stem cell transplant history. Out of the individuals with an overall response, 39% underwent hematopoietic stem cell transplant (HSCT), with eight of them not achieving a complete response (CR) or CR with partial hematologic recovery (CRh) before the transplant. Furthermore, the median overall survival was 8 months at the time of data cutoff.<\/strong><\/p>\n\n\n\n

In terms of safety analysis, revumenib demonstrated good tolerability, with a consistent and well-maintained safety profile. Among the 94 patients, Grade 3 differentiation syndrome (DS) occurred in 15%, while Grade 4 DS was observed in 1% of patients, and there were no Grade 5 DS. Additionally, Grade 3 QTc prolongation was noted in 14%, and no Grade 4 or 5 events were reported. Importantly, there were no trial discontinuations attributable to DS, cytopenias, or QTc prolongation.<\/p>\n\n\n\n

KOL Insights<\/strong><\/h2>\n\n\n\n
\n

“I am pleased that this pivotal dataset of revumenib as a monotherapy in heavily pretreated R\/R patients continues to support its profile as a potential best- and first-in-class therapy, Of particular note, the data presented today demonstrate rapid responses with revumenib, with a median time to CR\/CRh of 1.9 months, which is particularly impressive in this patient population. Responses were also observed across all major subgroups, with a similar CR\/CRh rate across adult and pediatric patients, which speaks to the wide clinical utility of revumenib across this underserved patient population.” \u2013Expert Opinion.<\/strong><\/p>\n<\/blockquote>\n\n\n\n

Conclusion<\/strong><\/h2>\n\n\n\n

The interim analysis of the combined KMT2Ar Acute Myeloid Leukemia Market and Acute Lymphocytic Leukemia cohorts in the pivotal AUGMENT-101 trial successfully achieved its primary endpoint, demonstrating a consistent CR\/CRh rate among both adult and pediatric patients.<\/p>\n\n\n\n

Refer to the Related Reports for More In-depth Insights –<\/strong><\/p>\n\n\n\n

\n
\n

Acute Lymphocytic Leukemia Market<\/a><\/strong><\/p>\n\n\n\n

Acute Myeloid Leukemia Market<\/a><\/strong><\/p>\n\n\n\n

Multiple Myeloma Market<\/a><\/strong><\/p>\n\n\n\n

Diffuse Large B-cell Lymphoma Market<\/a><\/strong><\/p>\n\n\n\n

Chronic Lymphocytic Leukemia Market<\/a><\/strong><\/p>\n<\/div>\n\n\n\n

\n

Hodgkin’s lymphoma Market<\/a><\/strong><\/p>\n\n\n\n

Mantle Cell Lymphoma Market<\/a><\/strong><\/p>\n\n\n\n

Myelofibrosis Market<\/a><\/strong><\/p>\n\n\n\n

Myelodysplastic Syndrome Market<\/a><\/strong><\/p>\n\n\n\n

Follicular Lymphoma Market<\/a><\/strong><\/p>\n<\/div>\n<\/div>\n","protected":false},"excerpt":{"rendered":"

Date of Abstract presentation 12th December 2023 Indications Acute Leukemia Abstract Number LBA-5 Abstract type Poster According to the data presented at the ASH 2023 conference, as of the July 2023 data cutoff, the pivotal trial AUGMENT-101 included 94 patients with acute leukemia within the KMT2Ar cohorts. Among them, 57 individuals received central confirmation of […]<\/p>\n","protected":false},"author":6,"featured_media":26177,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"_editorskit_title_hidden":false,"_editorskit_reading_time":0,"_editorskit_is_block_options_detached":false,"_editorskit_block_options_position":"{}","advgb_blocks_editor_width":"","advgb_blocks_columns_visual_guide":"","footnotes":""},"categories":[41],"tags":[20413,12078,12080,20004,21526,21525,21534,21533,17543,19905,137,841,927,18921,427],"industry":[17225],"therapeutic_areas":[17233,17228],"class_list":["post-26167","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-snippets","tag-abstracts","tag-acute-lymphocytic-leukemia","tag-acute-lymphocytic-leukemia-market","tag-american-society-of-hematology","tag-american-society-of-hematology-2023","tag-ash-2023","tag-ash-abstracts","tag-ash-annual-meeting-abstracts","tag-blood-cancer","tag-blood-diseases","tag-cancer","tag-cancer-research","tag-cancer-treatment","tag-hematology","tag-oncology","industry-pharmaceutical","therapeutic_areas-hematological-disorders","therapeutic_areas-oncology"],"acf":[],"yoast_head":"\nAUGMENT-101 Trial Hits Primary Endpoint R\/R Acute Leukemia<\/title>\n<meta name=\"description\" content=\"Revumenib monotherapy in R\/R KMT2Ar Acute Leukemia achieved topline efficacy and safety results from the pivotal Augment-101 Phase 2 Study\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.delveinsight.com\/blog\/augment-101-trial-hits-primary-endpoint\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"AUGMENT-101 Trial Hits Primary Endpoint R\/R Acute Leukemia\" \/>\n<meta property=\"og:description\" content=\"Revumenib monotherapy in R\/R KMT2Ar Acute Leukemia achieved topline efficacy and safety results from the pivotal Augment-101 Phase 2 Study\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.delveinsight.com\/blog\/augment-101-trial-hits-primary-endpoint\" \/>\n<meta property=\"og:site_name\" content=\"DelveInsight Business Research\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/DelveInsight-1423323754607782\/\" \/>\n<meta property=\"article:published_time\" content=\"2023-12-14T04:37:41+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2023-12-14T04:41:25+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2023\/12\/14100731\/augment-101-trial-hits-primary-endpoint.png\" \/>\n\t<meta property=\"og:image:width\" content=\"1200\" \/>\n\t<meta property=\"og:image:height\" content=\"800\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"DelveInsight\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@DelveInsight\" \/>\n<meta name=\"twitter:site\" content=\"@DelveInsight\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"DelveInsight\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"AUGMENT-101 Trial Hits Primary Endpoint R\/R Acute Leukemia","description":"Revumenib monotherapy in R\/R KMT2Ar Acute Leukemia achieved topline efficacy and safety results from the pivotal Augment-101 Phase 2 Study","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.delveinsight.com\/blog\/augment-101-trial-hits-primary-endpoint","og_locale":"en_US","og_type":"article","og_title":"AUGMENT-101 Trial Hits Primary Endpoint R\/R Acute Leukemia","og_description":"Revumenib monotherapy in R\/R KMT2Ar Acute Leukemia achieved topline efficacy and safety results from the pivotal Augment-101 Phase 2 Study","og_url":"https:\/\/www.delveinsight.com\/blog\/augment-101-trial-hits-primary-endpoint","og_site_name":"DelveInsight Business Research","article_publisher":"https:\/\/www.facebook.com\/DelveInsight-1423323754607782\/","article_published_time":"2023-12-14T04:37:41+00:00","article_modified_time":"2023-12-14T04:41:25+00:00","og_image":[{"width":1200,"height":800,"url":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2023\/12\/14100731\/augment-101-trial-hits-primary-endpoint.png","type":"image\/png"}],"author":"DelveInsight","twitter_card":"summary_large_image","twitter_creator":"@DelveInsight","twitter_site":"@DelveInsight","twitter_misc":{"Written by":"DelveInsight","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.delveinsight.com\/blog\/augment-101-trial-hits-primary-endpoint","url":"https:\/\/www.delveinsight.com\/blog\/augment-101-trial-hits-primary-endpoint","name":"AUGMENT-101 Trial Hits Primary Endpoint R\/R Acute Leukemia","isPartOf":{"@id":"https:\/\/www.delveinsight.com\/blog\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.delveinsight.com\/blog\/augment-101-trial-hits-primary-endpoint#primaryimage"},"image":{"@id":"https:\/\/www.delveinsight.com\/blog\/augment-101-trial-hits-primary-endpoint#primaryimage"},"thumbnailUrl":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2023\/12\/14100731\/augment-101-trial-hits-primary-endpoint.png","datePublished":"2023-12-14T04:37:41+00:00","dateModified":"2023-12-14T04:41:25+00:00","author":{"@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/0d96a31a370c143ffdb481d985d7edfd"},"description":"Revumenib monotherapy in R\/R KMT2Ar Acute Leukemia achieved topline efficacy and safety results from the pivotal Augment-101 Phase 2 Study","inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.delveinsight.com\/blog\/augment-101-trial-hits-primary-endpoint"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.delveinsight.com\/blog\/augment-101-trial-hits-primary-endpoint#primaryimage","url":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2023\/12\/14100731\/augment-101-trial-hits-primary-endpoint.png","contentUrl":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2023\/12\/14100731\/augment-101-trial-hits-primary-endpoint.png","width":1200,"height":800},{"@type":"WebSite","@id":"https:\/\/www.delveinsight.com\/blog\/#website","url":"https:\/\/www.delveinsight.com\/blog\/","name":"DelveInsight Business Research","description":"Blog","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.delveinsight.com\/blog\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/0d96a31a370c143ffdb481d985d7edfd","name":"DelveInsight","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/f9314f22b8c5b61d496451e91f32488d2457ecb59283b7b2ad7e82d330b47aba?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/f9314f22b8c5b61d496451e91f32488d2457ecb59283b7b2ad7e82d330b47aba?s=96&d=mm&r=g","caption":"DelveInsight"}}]}},"author_meta":{"display_name":"DelveInsight","author_link":"https:\/\/www.delveinsight.com\/blog\/author\/arawat"},"featured_img":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2023\/12\/14100731\/augment-101-trial-hits-primary-endpoint-300x200.png","coauthors":[],"tax_additional":{"categories":{"linked":["<a href=\"https:\/\/www.delveinsight.com\/blog\/snippets\/\" class=\"advgb-post-tax-term\">Snippets - A Small piece of News or Article<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">Snippets - A Small piece of News or Article<\/span>"]},"tags":{"linked":["<a href=\"https:\/\/www.delveinsight.com\/blog\/snippets\/\" class=\"advgb-post-tax-term\">Abstracts<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/snippets\/\" class=\"advgb-post-tax-term\">Acute lymphocytic leukemia<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/snippets\/\" class=\"advgb-post-tax-term\">Acute lymphocytic leukemia Market<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/snippets\/\" class=\"advgb-post-tax-term\">American Society of Hematology<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/snippets\/\" class=\"advgb-post-tax-term\">American Society Of Hematology 2023<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/snippets\/\" class=\"advgb-post-tax-term\">ASH 2023<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/snippets\/\" class=\"advgb-post-tax-term\">ASH Abstracts<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/snippets\/\" class=\"advgb-post-tax-term\">ASH Annual Meeting Abstracts<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/snippets\/\" class=\"advgb-post-tax-term\">Blood Cancer<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/snippets\/\" class=\"advgb-post-tax-term\">blood diseases<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/snippets\/\" class=\"advgb-post-tax-term\">Cancer<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/snippets\/\" class=\"advgb-post-tax-term\">Cancer research<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/snippets\/\" class=\"advgb-post-tax-term\">Cancer Treatment<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/snippets\/\" class=\"advgb-post-tax-term\">Hematology<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/snippets\/\" class=\"advgb-post-tax-term\">Oncology<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">Abstracts<\/span>","<span class=\"advgb-post-tax-term\">Acute lymphocytic leukemia<\/span>","<span class=\"advgb-post-tax-term\">Acute lymphocytic leukemia Market<\/span>","<span class=\"advgb-post-tax-term\">American Society of Hematology<\/span>","<span class=\"advgb-post-tax-term\">American Society Of Hematology 2023<\/span>","<span class=\"advgb-post-tax-term\">ASH 2023<\/span>","<span class=\"advgb-post-tax-term\">ASH Abstracts<\/span>","<span class=\"advgb-post-tax-term\">ASH Annual Meeting Abstracts<\/span>","<span class=\"advgb-post-tax-term\">Blood Cancer<\/span>","<span class=\"advgb-post-tax-term\">blood diseases<\/span>","<span class=\"advgb-post-tax-term\">Cancer<\/span>","<span class=\"advgb-post-tax-term\">Cancer research<\/span>","<span class=\"advgb-post-tax-term\">Cancer Treatment<\/span>","<span class=\"advgb-post-tax-term\">Hematology<\/span>","<span class=\"advgb-post-tax-term\">Oncology<\/span>"]}},"comment_count":"0","relative_dates":{"created":"Posted 2 years ago","modified":"Updated 2 years ago"},"absolute_dates":{"created":"Posted on Dec 14, 2023","modified":"Updated on Dec 14, 2023"},"absolute_dates_time":{"created":"Posted on Dec 14, 2023 10:07 am","modified":"Updated on Dec 14, 2023 10:11 am"},"featured_img_caption":"","series_order":"","_links":{"self":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/26167","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/users\/6"}],"replies":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/comments?post=26167"}],"version-history":[{"count":0,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/26167\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/media\/26177"}],"wp:attachment":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/media?parent=26167"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/categories?post=26167"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/tags?post=26167"},{"taxonomy":"industry","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/industry?post=26167"},{"taxonomy":"therapeutic_areas","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/therapeutic_areas?post=26167"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}